Amarin Corporation Reports Select Unaudited Financial Highlights for Q4 2025

Amarin Corporation (AMRN) has disclosed selected unaudited financial highlights for the fourth quarter and full year ended December 31, 2025, offering early insights into its financial trajectory. The company reported product revenue of $48.3 million for Q4 2025, reflecting a 12% year-over-year increase compared to $43.1 million in the same period of 2024. This growth was primarily attributed to increased prescription volume and expanded reimbursement coverage in key markets, including the United States and select European countries. For the full fiscal year 2025, Amarin reported unaudited product revenue of $182.6 million, up from $167.4 million in 2024. The company also noted that total operating expenses for the year were $135.8 million, including $78.3 million in research and development expenditures, underscoring its ongoing investment in pipeline advancement and regulatory submissions. Cash and cash equivalents at year-end stood at $124.5 million, supporting continued commercial operations and clinical development initiatives. The unaudited figures are subject to audit and may be revised upon finalization of financial statements. Despite this, the results indicate sustained momentum in the commercialization of Vascepa (icosapent ethyl), the company’s approved prescription omega-3 fatty acid therapy for high-risk cardiovascular patients. The data is expected to influence investor sentiment ahead of the company’s formal 2025 annual report and upcoming earnings call.